Literature DB >> 19011944

Risk stratification of patients with oral cavity squamous cell carcinoma and contralateral neck recurrence following radical surgery.

Chun-Ta Liao1, Shiang-Fu Huang, I-How Chen, Joseph Tung-Chieh Chang, Hung-Ming Wang, Shu-Hang Ng, Chuen Hsueh, Li-Yu Lee, Chih-Hung Lin, Ann-Joy Cheng, Tzu-Chen Yen.   

Abstract

Clinical outcome of patients with oral cavity squamous cell carcinoma (OSCC) and contralateral neck recurrence (CLNR) remains poor. We sought to identify factors associated with CLNR and incorporate them into a risk stratification scheme. Between January 1996 and June 2006, a total of 913 consecutive OSCC patients treated by radical surgery were investigated. Postoperative adjuvant therapy was performed in the presence of pathological risk factors. The duration of follow-up was at least 24 months in all surviving patients. Outcome measures were the 5-year CLNR and overall survival rates. In the entire study cohort, the 5-year CLNR rate was 7% (55/913). Specifically, it was 18% (17/132) in patients with local recurrence (LR), and 5% (38/781) in those without (P = 0.0002). In multivariate analysis, extracapsular spread (ECS) was the only independent risk factor for CLNR in patients with LR. Tumor subsite, poor differentiation, and presence of pN + disease were significant predictors of CLNR in patients without LR. We identified two groups of patients with high CLNR rates. The first group consisted of patients with ECS at the initial diagnosis and LR. The second group consisted of subjects with tongue cancer without LR harboring at least two risk factors. We conclude that, in patients who achieved local control, postoperative contralateral neck treatment is recommended for subjects with tongue cancer and at least two risk factors. Once LR occurs, contralateral neck treatment is recommended in patients with ECS.

Entities:  

Mesh:

Year:  2008        PMID: 19011944     DOI: 10.1245/s10434-008-0196-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  Computed tomography detection of extracapsular spread of squamous cell carcinoma of the head and neck in metastatic cervical lymph nodes.

Authors:  Joshua A Carlton; Adam W Maxwell; Lyndsey B Bauer; Sara M McElroy; Lester J Layfield; Humera Ahsan; Ajay Agarwal
Journal:  Neuroradiol J       Date:  2017-03-08

2.  Guidelines for the Surgical Management of Oral Cancer: Korean Society of Thyroid-Head and Neck Surgery.

Authors:  Young-Hoon Joo; Jae-Keun Cho; Bon Seok Koo; Minsu Kwon; Seong Keun Kwon; Soon Young Kwon; Min-Su Kim; Jeong Kyu Kim; Heejin Kim; Innchul Nam; Jong-Lyel Roh; Young Min Park; Il-Seok Park; Jung Je Park; Sung-Chan Shin; Soon-Hyun Ahn; Seongjun Won; Chang Hwan Ryu; Tae Mi Yoon; Giljoon Lee; Doh Young Lee; Myung-Chul Lee; Joon Kyoo Lee; Jin Choon Lee; Jae-Yol Lim; Jae Won Chang; Jeon Yeob Jang; Man Ki Chung; Yuh-Seok Jung; Jae-Gu Cho; Yoon Seok Choi; Jeong-Seok Choi; Guk Haeng Lee; Phil-Sang Chung
Journal:  Clin Exp Otorhinolaryngol       Date:  2019-02-02       Impact factor: 3.372

3.  Impact of a second FDG PET scan before adjuvant therapy for the early detection of residual/relapsing tumours in high-risk patients with oral cavity cancer and pathological extracapsular spread.

Authors:  Chun-Ta Liao; Kang-Hsing Fan; Chien-Yu Lin; Hung-Ming Wang; Shiang-Fu Huang; I-How Chen; Chung-Jan Kang; Shu-Hang Ng; Chuen Hsueh; Li-Yu Lee; Chih-Hung Lin; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-21       Impact factor: 9.236

4.  Pretreatment diffusion-weighted and dynamic contrast-enhanced MRI for prediction of local treatment response in squamous cell carcinomas of the head and neck.

Authors:  Sanjeev Chawla; Sungheon Kim; Lawrence Dougherty; Sumei Wang; Laurie A Loevner; Harry Quon; Harish Poptani
Journal:  AJR Am J Roentgenol       Date:  2013-01       Impact factor: 3.959

5.  Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS.

Authors:  Lang-Ming Chi; Chien-Wei Lee; Kai-Ping Chang; Sheng-Po Hao; Hang-Mao Lee; Ying Liang; Chuen Hsueh; Chia-Jung Yu; I-Neng Lee; Yin-Ju Chang; Shih-Ying Lee; Yuan-Ming Yeh; Yu-Sun Chang; Kun-Yi Chien; Jau-Song Yu
Journal:  Mol Cell Proteomics       Date:  2009-03-18       Impact factor: 5.911

6.  A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma.

Authors:  Chien-Hua Peng; Chun-Ta Liao; Shih-Chi Peng; Yin-Ju Chen; Ann-Joy Cheng; Jyh-Lyh Juang; Chi-Ying Tsai; Tse-Ching Chen; Yung-Jen Chuang; Chuan-Yi Tang; Wen-Ping Hsieh; Tzu-Chen Yen
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

7.  Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma.

Authors:  Chien-Hua Peng; Chun-Ta Liao; Ka-Pou Ng; An-Shun Tai; Shih-Chi Peng; Jen-Pao Yeh; Shu-Jen Chen; Kuo-Chien Tsao; Tzu-Chen Yen; Wen-Ping Hsieh
Journal:  Oncotarget       Date:  2015-08-14

8.  Clinical outcomes of patients with oral cavity squamous cell carcinoma and retropharyngeal lymph node metastasis identified by FDG PET/CT.

Authors:  Jing-Ren Tseng; Tsung-Ying Ho; Chien-Yu Lin; Li-Yu Lee; Hung-Ming Wang; Chun-Ta Liao; Tzu-Chen Yen
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

9.  Identification of High-Risk Subgroups of Patients With Oral Cavity Cancer in Need of Postoperative Adjuvant Radiotherapy or Chemo-Radiotherapy.

Authors:  Wen-Cheng Chen; Chia-Hsuan Lai; Chiung-Cheng Fang; Yao-Hsu Yang; Pau-Chung Chen; Chuan-Pin Lee; Miao-Fen Chen
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

10.  Endoplasmic reticulum aminopeptidase 2 involvement in metastasis of oral cavity squamous cell carcinoma discovered by proteome profiling of primary cancer cells.

Authors:  I-Chun Kuo; Huang-Kai Kao; Yenlin Huang; Chun-I Wang; Jui-Shan Yi; Ying Liang; Chun-Ta Liao; Tzu-Chen Yen; Chih-Ching Wu; Kai-Ping Chang
Journal:  Oncotarget       Date:  2017-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.